Lipocine Inc. reported a progress update on September 30, 2025, regarding its Phase 3 clinical trial for LPCN 1154, which is focused on treating Postpartum Depression (PPD). This filing signifies an important development in the company's research efforts, but is not marked as significant in terms of broader market impact.